Skip to main content

Table 1 The patients’ characteristics at diagnosis according to myelofibrosis (n = 316)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

  MF = 0/1 (n = 273) MF = 2/3 (n = 43) P
Age (years), median, range 52 (14–83) 52 (21–79) 0.705
Gender, no. (%)
 Male 181 (66.3%) 27 (62.8%) 0.652
 Female 92 (33.7%) 16 (37.2%)  
Median WBC (range), × 109/L 2.66 (0.27–13.47) 2.73 (1.10–12.00) 0.609
Median NE (range), × 109/L 0.99 (0.02–11.34) 0.85 (0.04–4.92) 0.794
Median HGB (range), g/L 69 (26–150) 67 (30–138) 0.291
Median PLT (range), × 109/L 53 (1–408) 47 (3–282) 0.911
MDS subtypes (WHO, 2016), no. (%) 0.243
 MDS-SLD 11 (4.0%) 2 (4.7%)  
 MDS-MLD 52 (19.1%) 4 (9.3%)  
 MDS-RS-SLD 2 (0.7%) 2 (4.7%)  
 MDS-RS-MLD 8 (2.9%) 3 (7.0%)  
 MDS with isolated 5q-deletion 2 (0.7%) 0 (0.0%)  
 MDS-EB-1 70 (25.7%) 10 (23.2%)  
 MDS-EB-2 118 (43.2%) 21 (48.8%)  
 MDS-U 10 (3.7%) 1 (2.3%)  
Cytogenetic 0.001
 Normal karyotype 148 (54.2%) 12 (27.9%)  
 Aberrant karyotype 125 (45.8%) 31 (72.1%)  
IPSS-R risk group, no. (%) 0.859
 Very low 4 (1.5%) 0 (0.0%)  
 Low 29 (10.6%) 5 (11.6%)  
 Intermediate 65 (23.8%) 9 (20.9%)  
 High 84 (30.8%) 12 (27.9%)  
 Very high 91 (33.3%) 17 (39.6%)  
Treatment, no. (%) 0.170
 Allogeneic HSCT 121 (44.3%) 20 (46.5%)  
 Cytoreductive treatments without HSCT 90 (33.0%) 12 (27.9%)  
  HMA 68 (25.0%) 10 (23.2%)  
  Chemotherapy combined with HMA 20 (7.3%) 2 (4.7%)  
  AML-like chemotherapy 2 (0.7%) 0 (0.0%)  
 Immunoregulatory 11 (4.0%) 5 (11.6%)  
 Supportive care 51 (18.7%) 6 (14.0%)  
Leukemia transformation, no. (%) 50 (18.3%) 8 (18.6%) 0.964
Median time from diagnosis to leukemia transformation, months (range) 12 (2–31) 7 (1–20) 0.043
  1. MF myelofibrosis, WBC white blood cell count, NE neutrophils, HGB hemoglobin, PLT platelet, MDS-SLD MDS with single-lineage dysplasia, MDS-MLD MDS with ring sideroblasts with multilineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts with single-lineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts with multilineage dysplasia, MDS-EB MDS with excess of blasts, MDS-U MDS unclassifiable, HSCT hematopoietic stem cell transplantation, HMA hypomethylating agents, AML acute myeloid leukemia